Product Details
| Product Name:
Succinobucol |
CAS No.:
216167-82-7 |
| Purity:
98.80% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | Succinobucol |
| Description | Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease. |
| Cell Research | In the metastatic 4T1 breast cancer cells, Succinobucol, SCB and the PCD polymer (equivalent concentration to SCB) are respectively added to each well with SCB concentrations ranging from 4 ng/mL to 40 μg/mL. |
| Animal Research | Mice, injected 4T1-luc cells, are treated with Succinobucol (40 mg/kg) by tail injection every three days. |
| In vitro | In rabbit whole blood, Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. |
| In vivo | In lung metastatic breast cancer mice, Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules. In rats, Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (72.94 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.24 mM), Sonication is recommended.
|
| Keywords | Succinobucol | ReactiveOxygenSpecies | Reactive Oxygen Species | Probucol Monosuccinate | Probucol | Inhibitor | inhibit | antioxidant | AGI1067 | AGI 1067 |
| Inhibitors Related | Ethoxyquin | Kaolin | Allopurinol | Cysteamine hydrochloride | Imeglimin hydrochloride | Ethyl linoleate | Magnesium acetate tetrahydrate | Inosine | L-Cystine | Dimethyl itaconate | L-Ascorbic acid sodium salt | Dimethyl phthalate |
| Related Compound Libraries | NF-κB Signaling Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Pyroptosis Compound Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States